Vosoritide therapy in children with achondroplasia under 5 years of age.

Administration of vosoritide at a dose of 15.0 μg/kg per day in children aged 5–18 years resulted in a highly significant increase in annualized growth velocity and height Z score after 52 weeks of treatment compared with those receiving placebo ( 21 ).

also in 132,142 other papers